ArticleESC heart failure2025
Short report: Hospitalization for new-onset heart failure in survivors of hospitalized COVID-19.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incident Heart Failure Risk Following COVID-19 Recovery: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Short report: Hospitalization for new-onset heart failure in survivors of hospitalized COVID-19.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsPrevious studies have reported an incidence of new-onset heart failure (HF) among COVID-19 survivors ranging from 0.7 to 8.5 per 100 person-years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post-COVID-19 is important. METHODS AND
resultsWe conducted a prospective cohort study of survivors of hospitalized COVID-19 and tracked the incidence of new-onset HF hospitalizations over the 12-month period following the index COVID-19 episode. Outcome ascertainment was based on a combination of chart reviews, patient interviews, and pre-specified clinical, radiographic and laboratory criteria. We identified 2140 survivors of COVID-19 hospitalization that were free of HF at the time of discharge. Their mean age was 67 years and 48% were Black/African-Americans. The incidence rate of hospitalized new-onset HF was 0.5 per 100 person-years. Higher BMI and dialysis dependency at baseline were significantly associated with HF development. The 1-year mortality rate was 3%.
conclusionsThe incidence of new-onset HF post-COVID-19 in our study was lower than in previous reports, despite involving an older population with more comorbidities and/or more severe COVID-19 overall. Reliance on administrative data for outcome adjudication in prior studies may have led to an overestimation of the HF burden post-COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.